← Leaderboards
Philip Pemberton
Serplus Technology, Llc
$603,638
Attributed
$947,662
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $441.8K · FY2018–22$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$688,049 · 3
CDC$259,613 · 1
By mechanism
R41$688,049 · 3
R43$259,613 · 1
Top collaborators
- Rohit N. Kulkarni2 shared
- David H Broide1 shared
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseInflammationPreventRecombinantsTechnologyCellsPeptide HydrolasesEfficacy StudyProductionProteinsSerpinsSkillsOutcome StudyMouse ModelAnimal ModelElastasesDesignBaseFutureIn VitroInflammatoryMortalityAlpha 1-AntitrypsinMediating
Grant awards (4)
PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza$259,613
R43 · FY2022 · IP · contact PI
Enhanced pancreatic islet cell engraftment by treatment with serpin B1$246,281
R41 · FY2021 · DK · contact PI
Amelioration of rhinovirus induced asthma exacerbations by serpin B1$223,334
R41 · FY2018 · AI · contact PI
Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin)$218,434
R41 · FY2018 · DK · contact PI